Adaption and Validation of PROMIS for use in Vasculitis

PROMIS 用于血管炎的调整和验证

基本信息

  • 批准号:
    8461762
  • 负责人:
  • 金额:
    $ 41.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-15 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overarching goal of the proposed work is to more effectively incorporate patients' perspectives into the assessment of disease activity and burden among patients with ANCA-associated vasculitis [AAV, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and Churg-Strauss syndrome]. This project seeks to demonstrate the validity and feasibility of incorporating the Patient Reported Outcomes Measurement System (PROMIS) into clinical research in AAV. This project has five specific aims: Specific Aim 1: Determine the construct validity of PROMIS instruments in AAV through cross-sectional analysis of subjects within the Vasculitis Clinical Research Consortium (VCRC) patient cohort, utilizing other HRQOL instruments and physician-determined measures of vasculitis disease activity and damage as constructs. Specific Aim 2: Determine the longitudinal validity, responsiveness, and clinically important difference for the PROMIS instruments in an AAV population by comparing changes over time to the clinical evaluation, fatigue SF-36, and a patient global impression of change measure. Specific Aim 3: Determine the additive/complementary value of PROMIS assessments in defining the disease beyond standard measures of HRQOL and disease activity in AAV. Specific Aim 4: Use selected PROMIS instruments in a randomized therapeutic clinical trial in AAV. Specific Aim 5: Establish a "tool box" of PROMIS symptomatic measures that are the most useful for clinical research in AAV by assessing i) patients' ratings of the importance of the instrument domains; ii) the usefulness in describing the extent of the disease process; and iii) the relative efficiency and feasibility of the use of various PROMIS instruments in an RCT; and then providing researchers with informed guidance to integrate PROMIS into clinical investigation of AAV. The study will be conducted by the Vasculitis Clinical Research Consortium (VCRC), the largest collaborative clinical research infrastructure in North America and is fully responsive to the NIH RFA for PROMIS by utilizing already-established research cohorts and resources, including i) the VCRC Longitudinal Study cohorts for AAV; ii) the RITAZAREM clinical trial in AAV; and iii) the on-line VCRC Patient Contact Registry. PUBLIC HEALTH RELEVANCE: The proposed project will explore novel methods to incorporate how patients with vasculitis feel about the burden of their disease into clinical research in order to both better understand the disease and to help develop a set of research tools to measure the disease from the patients' perspective. The project will test the Patient Reported Outcomes Measurement System (PROMIS), a highly advanced system developed by the NIH to measure patients' ratings of disease-related health problems. The research will produce important advances to provide a method to incorporate patients' own assessments of their disease into research. This project is fully relevant to the mission and goals of the Nationa Institutes of Health.
描述(由申请人提供):拟议工作的总体目标是更有效地将患者的观点纳入对 ANCA 相关血管炎 [AAV、肉芽肿性多血管炎(韦格纳氏)、显微镜下多血管炎、和 Churg-Strauss 综合征]。该项目旨在证明将患者报告结果测量系统 (PROMIS) 纳入 AAV 临床研究的有效性和可行性。该项目有五个具体目标: 具体目标 1:通过对血管炎临床研究联盟 (VCRC) 患者队列中的受试者进行横断面分析,利用其他 HRQOL 工具和医生确定的血管炎测量方法,确定 AAV 中 PROMIS 工具的结构有效性疾病活动和损害作为结构。具体目标 2:通过将随时间的变化与临床评估、疲劳 SF-36 和患者对变化测量的总体印象进行比较,确定 PROMIS 仪器在 AAV 群体中的纵向有效性、响应性和临床重要差异。 具体目标 3:确定 PROMIS 评估在定义疾病方面超出 HRQOL 和 AAV 疾病活动标准测量的附加/补充价值。 具体目标 4:在 AAV 随机治疗临床试验中使用选定的 PROMIS 仪器。 具体目标 5:通过评估 i) 患者对仪器领域重要性的评级,建立对 AAV 临床研究最有用的 PROMIS 症状测量“工具箱”; ii) 描述疾病过程范围的有用性; iii) 在 RCT 中使用各种 PROMIS 工具的相对效率和可行性;然后为研究人员提供知情指导,将 PROMIS 整合到 AAV 的临床研究中。该研究将由血管炎临床研究联盟 (VCRC) 进行,该联盟是北美最大的合作临床研究基础设施,并利用现有的研究队列和资源,充分响应 NIH RFA for PROMIS,包括 i) VCRC Longitudinal AAV 研究队列; ii) AAV 的 RITAZAREM 临床试验; iii) 在线 VCRC 患者联系登记处。 公共健康相关性:拟议的项目将探索新方法,将血管炎患者对其疾病负担的感受纳入临床研究,以便更好地了解这种疾病,并帮助开发一套研究工具来衡量这种疾​​病患者的观点。该项目将测试患者报告结果测量系统(PROMIS),这是一个由 NIH 开发的高度先进的系统,用于测量患者对疾病相关健康问题的评分。该研究将取得重要进展,提供一种将患者自己对疾病的评估纳入研究的方法。该项目与国家卫生研究院的使命和目标完全相关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter A Merkel其他文献

Glucocorticoid Minimization in ANCA-Associated Vasculitis: An International Survey of Clinicians
ANCA 相关血管炎中糖皮质激素最小化:一项国际临床医生调查
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    D. Massicotte;M. Canney;Priscilla Karnabi;Peter A Merkel;Rachel B. Jones;Ruth J. Pepper;Alan D. Salama;V. Derebail;N. Milman;Mats Junek;C. Pagnoux;David R W Jayne;Michael Walsh
  • 通讯作者:
    Michael Walsh
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
贝那利珠单抗与美泊利珠单抗治疗嗜酸性肉芽肿性多血管炎。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    158.5
  • 作者:
    Michael E. Wechsler;P. Nair;Benjamin Terrier;Bastian Walz;Arnaud Bourdin;D. Jayne;David J Jackson;F. Roufosse;L. Börjesson Sjö;Ying Fan;M. Jison;C. McCrae;S. Necander;A. Shavit;C. Walton;Peter A Merkel
  • 通讯作者:
    Peter A Merkel

Peter A Merkel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter A Merkel', 18)}}的其他基金

VCRC Genetics and Genomics Program
VCRC 遗传学和基因组学计划
  • 批准号:
    8919980
  • 财政年份:
    2015
  • 资助金额:
    $ 41.66万
  • 项目类别:
VCRC Clinical Outcomes Program
VCRC 临床结果计划
  • 批准号:
    8919981
  • 财政年份:
    2015
  • 资助金额:
    $ 41.66万
  • 项目类别:
Longitudinal Studies for Vasculitis
血管炎的纵向研究
  • 批准号:
    8919978
  • 财政年份:
    2015
  • 资助金额:
    $ 41.66万
  • 项目类别:
Adaption and Validation of PROMIS for use in Vasculitis
PROMIS 用于血管炎的调整和验证
  • 批准号:
    8545674
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Adaption and Validation of PROMIS for use in Vasculitis
PROMIS 用于血管炎的调整和验证
  • 批准号:
    8708763
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Adaption and Validation of PROMIS for use in Vasculitis
PROMIS 用于血管炎的调整和验证
  • 批准号:
    8917091
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Conference on Clinical Research for Rare Diseases
罕见病临床研究会议
  • 批准号:
    8245565
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:
Conference on Clinical Research for Rare Diseases
罕见病临床研究会议
  • 批准号:
    8048115
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:
Conference on Clinical Research for Rare Diseases
罕见病临床研究会议
  • 批准号:
    7806262
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:
Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis
血浆置换和糖皮质激素治疗 ANCA 相关性血管炎
  • 批准号:
    8537733
  • 财政年份:
    2009
  • 资助金额:
    $ 41.66万
  • 项目类别:

相似海外基金

Developing a nonpharmacological pain intervention for community dwelling older adults with dementia
为社区居住的痴呆症老年人开发非药物疼痛干预措施
  • 批准号:
    10644490
  • 财政年份:
    2023
  • 资助金额:
    $ 41.66万
  • 项目类别:
Effects of mild traumatic brain injury in a mouse model of cerebral amyloid angiopathy
轻度创伤性脑损伤对脑淀粉样血管病小鼠模型的影响
  • 批准号:
    10648555
  • 财政年份:
    2023
  • 资助金额:
    $ 41.66万
  • 项目类别:
Boxing Day: Time and Contradiction in Transgender Poetry
节礼日:跨性别诗歌中的时间与矛盾
  • 批准号:
    2889741
  • 财政年份:
    2023
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Studentship
Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
日常生活中的活动能力和帕金森病的跌倒:康复的潜力
  • 批准号:
    10630819
  • 财政年份:
    2020
  • 资助金额:
    $ 41.66万
  • 项目类别:
Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
日常生活中的活动能力和帕金森病的跌倒:康复的潜力
  • 批准号:
    10434015
  • 财政年份:
    2020
  • 资助金额:
    $ 41.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了